Phyla
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Phyla - overview
Established
2014
Location
-, CA, US
Primary Industry
Healthcare Specialists
About
Based in California, US, and founded in 2014, Phi Therapeutics, Inc. , dba Phyla, offers a cleanser, bacteriophage serum, and moisturizer system to cure Cutibacterium acnes. Maria Cho and Yug Varma (CEO) are the co-founders of the company. In July 2022, Phyla raised USD 2 million in growth funding from Joyance Partners, Maximum Effort Holdings, N+1, Progression Fund, Willow Growth Partners, and an individual investor.
The company provides products including phresh gel cleanser, acne fighting phage serum, phluff moisturizer, and a 3-step acne-fighting phage kit. Phyla's products kill bad bacteria, improve acne, and recalibrate the microbiome for long-term skin health. The firm uses microbiome research and bacteriophage technology to develop new approaches to acne and other chronic diseases.
Current Investors
N+1, Joyance Partners, Progression
Primary Industry
Healthcare Specialists
Sub Industries
Beauty & Hygiene, Biotechnology, Dermatology
Website
www.phylabiotics.com
Company Stage
Growth Stage/Expansion
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.